In April, Nhwa holding subsidiary, Beijing Hao Xinqing Mobile Medical Technology Co., Ltd., Was established.
In April, passed the assessment of Integration of Informatization and Industrialization and obtained the certificate.
In May, Beijing Yihua Mobile Medical Technology Co., Ltd. was established
In June, signed agreement with US company, Ladbrokes, regarding "Product license and share subscription agreement" on the exclusive license of propofol injection.
In September, signed agreement with Israel Mapi Corporation regarding "Equity subscription agreement" on the subscription of B shares.
In September, the holding subsidiary Jiangsu Nhwa Run Pharmaceutical Co., Ltd. acquired the Certificate of online drug trading service.
In October, Xuzhou Nhwa Import and Export Trade Co., Ltd. completed its business registration.
In January, Nhwa passed high-tech enterprises accreditation again.
In February, Nhwa International API production base was completed, passing the GMP certification.
In March, Provincial International Cooperation Program---the first type of new drug (FTND) DP-VPA and its tablets passed quality acceptance.
In March, the first type of new drug (FTND) DP-VPA and its tablets acquired clinical experiment approved document.
In June, Jiawang branch of Jiangsu Nhwa Pharmaceutical Co., Ltd. was established.
In July, refinancing was completed with 13.42 million non-public shares.
In September, Jiangsu Hao Xinqing Mobile Medical Technology Co., Ltd was established.
In December, Nhwa established its International Pharmaceutical Research Institute.
In January, the renewal of Fenofibrate CEP Certificate was completed.
In March," Nhwa " was identified as the first Xuzhou famous trade name.
In May, Nhwa ranked 92th in Top 100 in China's pharmaceutical industry in 2013.
In June, Freeze-dried powder injection workshop obtained GMP certificate.
In August, Nhwa CNS R&D center came into use.
In August, Nhwa Research Institute was set up..
In September, Jiangsu Nhwa Luokang Pharmaceutical Development Co., Ltd. was established
In September, remifentanil hydrochloride for injection approved by SFDA.
In November, the company launched a pre-arranged plan for non-public A shares.
In November, Nhwa’s branch companies, Nhwa-Hexin Pharam., Nhwa-Run Midicine and Nhwa Chain pharmacy passed GSP certification. And Nhwa logistics park came into use.
In December, Aripiprazole API and its tablets are approved.
In January, small-volumn injection workshops in Nhwa Tongshan Industrial Park passed GMP inspection and got the certificate.
In June, Nhwa ranked 93th in Top 100 in China Pharmaceutical Industry in 2012.
In July, Dloxetine hydrochloride API and Dloxetine hydrochloride enteric-coated tablets approved by SDFA.
In September, Duloxetine hydrochloride API obtained GMP certificate, and successfully appeared on the market.
In December, small-volumn injection workshops in Nhwa Jinshanqiao Industrial Park passed GMP inspection , and obtained the certificate.
In January, the preclinical research project of XP080319-3 as a new non-opioid anti-neuralgia drug, the project of new antiepileptic drug DP-VPA and its formulation, the project of new multi-target anti-schizophrenia drug project were listed in the "National major new drug intitiative".
In April, Propofol API and propofol injection approved by SFDA.
In April, Nhwa’s solid preparations got the GMP certificates as well as Fentanyl Citrate API.
In August, Nhwa’s tablet and hard capsule production line obtained GMP certificates, as well as propofol API.
In October, Nhwa R&D Center was identified as the nineteenth batch of "National identified enterprise technology center" by national ministries and commissions.
In January, Antipsychotic ziprasidone and its preparation process improvement project was listed in the "National major new drug intitiative"
In January, Nhwa was chosen as key high-tech enterprises in the National Torch Program by the State Ministry of Science and Technology.
In August, Dexmedetomidine Hydrochloride API and Dexmedetomidine Hydrochloride injection were approved by the SFDA.
In September, Vecuronium Bromide API was approved by the SFDA.
In September, Nhwa passed high-tech enterprises re-certification and obtained GMP certificate.
In Noverber, Dexmedetomidine Hydrochloride and Vecuronium Bromide passed GMP inspection and obtained the certificates.
In December, Fentanyl Citrate API and Fentanyl Citrate injection were approved by the SFDA.
In December, Jiangsu CNS medicine engineering center was established with the approval of Jiangsu Provincial Science and Technology Department.
In March, Midazolam Maleate obtained GMP certificate.
In June, Nhwa passed the acceptance inspection on clean production.
In August, new formulation of risperidone dispersible tablets and the new formulation of clozapine orally disgrating tablets were approved by the SFDA.
In November, Jiawang International API production base held the foundation stone laying ceremony
In November, Risperidone, riluzole, nitrazepine, lithium carbonate, ketoconazole, clomipramine hydrochloride and nizatidine API passed GMP re- certification and obtained GMP certificates.
In January, gabapentine API workshop successfully passed the inspection by the Germany Authority.
In February, gabapentin API got the EU GMP certificate.
In February, ziprasidone mesylate API and Ziprasidone mesylate injection approved by SFDA.
In April, fenofibrate obtained the CEP certificate.
In August, gabapentin, naproxen, ropivacaine mesylate, psychotropic drug (nitrazepam), etomidate, doxapramine hydrochloride, buspirone hydrochloride, psychotropic drugs (triazolam, midazolam, zaleplon,) API obtained GMP certification.
In January, the clinical research project of the innovative hypertension drug Iptakalim, the research project of YX0611-1 and compounds with characteristics of finished products as new non-opioid anti-neuralgia drug were listed in the "National major new drug initiatives".
In February, Nhwa headquarter relocated to No.69, Nhwa Building, South Mingzhu Road
In July, Nhwa listed in the Shenzhen Stock Exchange on July 23th, 2008
In October, Nhwa obtained high-tech enterprise certificate
In December ,"Nhwa" got the certificate of Jiangsu famous brand name, No:  078
In December, Nhwa was identified as Jiangsu second batch of high-tech enterprises in 2008 with the validity of three years.
Changed name to "Jiangsu Nhwa Pharmaceutical Co., Ltd."
“Nhwa " was identified as" Jiangsu famous brand name", and name changed to "Jiangsu Nhwa Pharmaceutical Group Co., Ltd."
“Nhwa " was identified as Xuzhou famous brand name
Nhwa was defined as a state-level high-tech enterprises by the State Ministry of Science and Technology.
The company performed a second restructuring with the adjustment of stock right, and state-owned capital withdrew.
Xuzhou Nhwa Pharmaceutical Group Co., Ltd. was set up.
Based on the Third Xuzhou pharmaceutical factory, Xuzhou Nhwa Pharmaceutical Group was established.
The company was dubbed advanced technological enterprise in Jiangsu Province by Jiangsu Provincial Government,
'Nhwa ' trademark was registered
Approved as the high-tech enterprises in Jiangsu Province.
Triazolam was approved for production.
Miconazole nitrate got production approval by Jiangsu Health Ministry.
The national innovative antiepileptic drug "clonidine" was put into production.
The third branch of Xuzhou pharmaceutical factory changed its name to the Third Xuzhou pharmaceutical factory.
The third branch of Xuzhou pharmaceutical factory was established .